Theravance Biopharma, Inc. (NASDAQ:TBPH) – Leerink Swann lifted their FY2017 earnings estimates for Theravance Biopharma in a report issued on Wednesday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will post earnings per share of ($4.95) for the year, up from their prior forecast of ($5.10). Leerink Swann also issued estimates for Theravance Biopharma’s Q4 2017 earnings at ($1.16) EPS, FY2018 earnings at ($4.75) EPS, FY2019 earnings at ($4.52) EPS, FY2020 earnings at ($3.78) EPS and FY2021 earnings at ($1.76) EPS.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/12/leerink-swann-research-analysts-lift-earnings-estimates-for-theravance-biopharma-inc-tbph.html.
Other research analysts have also issued reports about the stock. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, August 16th. Evercore ISI assumed coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 target price for the company. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. BidaskClub lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $41.86.
Theravance Biopharma (NASDAQ TBPH) opened at $28.77 on Friday. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The company has a debt-to-equity ratio of 1.21, a quick ratio of 6.53 and a current ratio of 7.53.
Hedge funds and other institutional investors have recently bought and sold shares of the business. QS Investors LLC purchased a new position in Theravance Biopharma during the second quarter worth $100,000. Ameritas Investment Partners Inc. boosted its stake in Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 230 shares during the period. Aperio Group LLC purchased a new stake in shares of Theravance Biopharma during the second quarter valued at $205,000. BNP Paribas Arbitrage SA boosted its stake in shares of Theravance Biopharma by 570.7% during the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 4,383 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of Theravance Biopharma during the second quarter valued at $214,000. 84.54% of the stock is owned by institutional investors.
In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the transaction, the executive vice president now directly owns 134,327 shares of the company’s stock, valued at $4,133,241.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Frank Pasqualone acquired 4,000 shares of the company’s stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of $26.34 per share, with a total value of $105,360.00. Following the completion of the purchase, the senior vice president now directly owns 213,180 shares of the company’s stock, valued at $5,615,161.20. The disclosure for this purchase can be found here. 6.10% of the stock is owned by insiders.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.